281 related articles for article (PubMed ID: 29722791)
1. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
Schwartzberg L; Roeland E; Andric Z; Kowalski D; Radic J; Voisin D; Rizzi G; Navari R; Gralla RJ; Karthaus M
Ann Oncol; 2018 Jul; 29(7):1535-1540. PubMed ID: 29722791
[TBL] [Abstract][Full Text] [Related]
2. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
Rugo HS; Rossi G; Rizzi G; Aapro M
Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
Aapro M; Jordan K; Gralla RJ; Rizzi G; Rossi G; Palmas M; Alyasova AV; Lisyanskaya AS; Bošnjak SM; Hesketh PJ
J Geriatr Oncol; 2017 Jan; 8(1):56-63. PubMed ID: 27889278
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S
Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643
[TBL] [Abstract][Full Text] [Related]
7. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Kurteva G; Chilingirova N; Rizzi G; Caccia T; Stella V; Bernareggi A
Eur J Pharm Sci; 2019 Nov; 139():105041. PubMed ID: 31404621
[TBL] [Abstract][Full Text] [Related]
9. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E
Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813
[TBL] [Abstract][Full Text] [Related]
10. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H
Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469
[TBL] [Abstract][Full Text] [Related]
11. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V
Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Hesketh PJ; Rossi G; Rizzi G; Palmas M; Alyasova A; Bondarenko I; Lisyanskaya A; Gralla RJ
Ann Oncol; 2014 Jul; 25(7):1340-1346. PubMed ID: 24608196
[TBL] [Abstract][Full Text] [Related]
14. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
16. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
17. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
Hesketh PJ; Palmas M; Nicolas P
Support Care Cancer; 2018 Apr; 26(4):1151-1159. PubMed ID: 29080920
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
19. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
[TBL] [Abstract][Full Text] [Related]
20. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
Aapro M; Zhang L; Yennu S; LeBlanc TW; Schwartzberg L
Future Oncol; 2019 Apr; 15(10):1067-1084. PubMed ID: 30860400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
